Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Won‐Gun Yun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4023-4739; OpenAlex author ID A5033679569. Sources: OpenAlex.

Their work

Papers
35 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2022: 3 papers · 2023: 2 papers · 2024: 14 papers · 2025: 13 papers · 2026: 3 papers

Papers 35

  1. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Co-author DOI 10.1016/j.suronc.2026.102368↗
  2. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Co-author DOI 10.1245/s10434-025-18349-8↗
  3. Correction: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: … Co-author DOI 10.1245/s10434-026-20624-1↗
  4. Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Co-author DOI 10.1002/jhbp.12122↗
  5. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-11833-y↗
  6. Prognostic implications of resection margin status in distal pancreatectomy for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.hpb.2025.04.001↗
  7. Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenoca… Co-author DOI 10.1038/s12276-024-01382-0↗
  8. SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. Co-author DOI 10.1038/s12276-025-01596-w↗
  9. Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitiviti… Co-author DOI 10.1186/s12935-025-03671-8↗
  10. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… Co-author DOI 10.1245/s10434-024-16743-2↗
  11. ASO Author Reflections: Is There an Extra Benefit of Adding Neoadjuvant Radiotherapy to Chemotherapy in Patients with (Borderline) Resectable Pancreatic Cancer? Co-author DOI 10.1245/s10434-024-16829-x↗
  12. Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… Co-author DOI 10.1245/s10434-025-17389-4↗
  13. ASO Author Reflections: In the Era of Neoadjuvant Chemotherapy for Pancreatic Cancer, Should the Definition of Resection Margin Change or Stay the Same? Co-author DOI 10.1245/s10434-025-17460-0↗
  14. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Co-author DOI 10.1245/s10434-025-18123-w↗
  15. Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy. Co-author DOI 10.3390/nu17040647↗
  16. Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic duc… Co-author DOI 10.4174/astr.2025.109.2.61↗
  17. Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cac2.12585↗
  18. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. Co-author DOI 10.1002/jhbp.12048↗
  19. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  20. Emerging role of local treatment in the era of advanced systemic treatment in pancreatic cancer with liver metastasis: A systematic review and meta-analysis. Co-author DOI 10.1002/jhbp.12051↗
  21. Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/jhbp.1352↗
  22. Prospective Comparison of [18F]FDG and [18F]AIF-FAPI-74 PET/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11307-024-01950-w↗
  23. Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant… Co-author DOI 10.1016/j.hpb.2023.11.015↗
  24. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2024.100824↗
  25. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000001184↗
  26. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond … Co-author DOI 10.1097/js9.0000000000002034↗
  27. Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. Co-author DOI 10.1186/s12885-024-12795-5↗
  28. In Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Ductal Adenocarcinoma, Which Response is the More Reliable Indicator for Prognosis, Radiologic or Biochem… Co-author DOI 10.1245/s10434-023-14532-x↗
  29. ASO Author Reflections: What is the Optimal Method for Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-023-14658-y↗
  30. Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.3390/biomedicines13010062↗
  31. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score… Co-author DOI 10.1002/jhbp.1313↗
  32. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer… Co-author DOI 10.1007/s11605-023-05850-2↗
  33. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohor… Co-author DOI 10.1093/clinchem/hvac153↗
  34. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Co-author DOI 10.3390/cancers14092067↗
  35. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers14184360↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 33 shared papers, 2022–2026 · strength 7.73
  2. Jin‐Young Jang · 30 shared papers, 2022–2026 · strength 7.28
  3. Hye‐Sol Jung · 26 shared papers, 2022–2026 · strength 5.93
  4. Yoon Soo Chae · 12 shared papers, 2024–2026 · strength 2.92
  5. Mirang Lee · 13 shared papers, 2022–2025 · strength 2.70
  6. Joon Seong Park · 9 shared papers, 2024–2026 · strength 2.23
  7. Go‐Won Choi · 8 shared papers, 2025–2026 · strength 2.05
  8. Younsoo Seo · 6 shared papers, 2025–2026 · strength 1.54
  9. Young‐Jae Cho · 4 shared papers, 2024–2025 · strength 0.85
  10. Youngmin Han · 3 shared papers, 2025–2026 · strength 0.76
  11. Michael D. Kluger · 4 shared papers, 2022–2024 · strength 0.73
  12. Alexander S. Thomas · 4 shared papers, 2022–2024 · strength 0.73
  13. Seulah Park · 3 shared papers, 2024–2025 · strength 0.69
  14. Daechan Park · 3 shared papers, 2024–2025 · strength 0.69
  15. Do‐Youn Oh · 2 shared papers, 2024–2025 · strength 0.45
  16. Eui Kyu Chie · 2 shared papers, 2024–2025 · strength 0.45
  17. Sang Hyub Lee · 2 shared papers, 2024–2025 · strength 0.45
  18. Ja‐Lok Ku · 2 shared papers, 2024–2025 · strength 0.45
  19. Jin‐Young Jang · 2 shared papers, 2024 · strength 0.38
  20. Hyeong Seok Kim · 2 shared papers, 2022 · strength 0.29
  21. Hongbeom Kim · 2 shared papers, 2022 · strength 0.28
  22. Ha Eun Kim · 1 shared paper, 2025 · strength 0.26
  23. Joon Seong Park · 1 shared paper, 2025 · strength 0.25
  24. Yoo‐Seok Yoon · 1 shared paper, 2025 · strength 0.25
  25. Ju Eun Maeng · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.